EA201892774A1 - Антитела - Google Patents
АнтителаInfo
- Publication number
- EA201892774A1 EA201892774A1 EA201892774A EA201892774A EA201892774A1 EA 201892774 A1 EA201892774 A1 EA 201892774A1 EA 201892774 A EA201892774 A EA 201892774A EA 201892774 A EA201892774 A EA 201892774A EA 201892774 A1 EA201892774 A1 EA 201892774A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- antibody
- binding fragment
- compositions containing
- dna
- antibodies
- Prior art date
Links
- 239000012634 fragment Substances 0.000 abstract 4
- 206010016654 Fibrosis Diseases 0.000 abstract 1
- 102000004887 Transforming Growth Factor beta Human genes 0.000 abstract 1
- 108090001012 Transforming Growth Factor beta Proteins 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 230000004761 fibrosis Effects 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
- A61K2039/541—Mucosal route
- A61K2039/544—Mucosal route to the airways
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/12—Mucolytics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Immunology (AREA)
- Pulmonology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Otolaryngology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Pyridine Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Indole Compounds (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
Настоящее раскрытие относится к антителам против TGF-beta и их связывающим фрагментам, к ДНК, их кодирующим, клеткам-хозяевам, содержащим указанную ДНК, и к способам экспрессии антитела или связывающего фрагмента в клетке-хозяине. Раскрытие также распространяется на фармацевтические композиции, содержащие антитело или его связывающий фрагмент, и на применение антитела, связывающего фрагмента и композиций, их содержащих, при лечении различных заболеваний, включающих фиброз.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1610044.8A GB201610044D0 (en) | 2016-06-08 | 2016-06-08 | Antibodies |
| PCT/EP2017/063796 WO2017211873A1 (en) | 2016-06-08 | 2017-06-07 | Antagonist antibodies that t bind to human tgfb1, tgfb2 and to tgfb3 and their use for the treatment of lung fibrosis |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| EA201892774A1 true EA201892774A1 (ru) | 2019-05-31 |
Family
ID=56508288
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EA201892774A EA201892774A1 (ru) | 2016-06-08 | 2017-06-07 | Антитела |
Country Status (20)
| Country | Link |
|---|---|
| US (2) | US10766956B2 (ru) |
| EP (1) | EP3468992A1 (ru) |
| JP (1) | JP2019520818A (ru) |
| KR (1) | KR20190015497A (ru) |
| CN (1) | CN109311970A (ru) |
| AR (1) | AR108779A1 (ru) |
| AU (1) | AU2017276685A1 (ru) |
| BR (1) | BR112018074869A2 (ru) |
| CA (1) | CA3024011A1 (ru) |
| CL (1) | CL2018003510A1 (ru) |
| CO (1) | CO2018012513A2 (ru) |
| EA (1) | EA201892774A1 (ru) |
| GB (1) | GB201610044D0 (ru) |
| IL (1) | IL263425A (ru) |
| MX (1) | MX2018014376A (ru) |
| RU (1) | RU2746926C2 (ru) |
| SG (1) | SG11201810311WA (ru) |
| TW (1) | TW201802115A (ru) |
| UY (1) | UY37279A (ru) |
| WO (1) | WO2017211873A1 (ru) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4467565A3 (en) | 2016-12-21 | 2025-03-12 | Amgen Inc. | Anti-tnf alpha antibody formulations |
| DK3579848T3 (da) | 2017-02-08 | 2025-01-20 | Dragonfly Therapeutics Inc | Multispecifikke bindende proteiner til aktivering af naturlige dræberceller og terapeutiske anvendelser heraf til behandling af kræft |
| KR20240060739A (ko) | 2017-02-20 | 2024-05-08 | 드래곤플라이 쎄라퓨틱스, 인크. | Her2, nkg2d 및 cd16에 결합하는 단백질 |
| PE20210375A1 (es) * | 2018-02-08 | 2021-03-02 | Dragonfly Therapeutics Inc | Terapia de combinacion del cancer que incluye proteinas de union multiespecificas que activan a las celulas asesinas naturales |
| CA3090244A1 (en) | 2018-02-08 | 2019-08-15 | Dragonfly Therapeutics, Inc. | Antibody variable domains targeting the nkg2d receptor |
| WO2019164930A1 (en) | 2018-02-20 | 2019-08-29 | Dragonfly Therapeutics, Inc. | Multi-specific binding proteins that bind cd33, nkg2d, and cd16, and methods of use |
| JP7540994B2 (ja) | 2018-07-11 | 2024-08-27 | スカラー ロック インコーポレイテッド | 高親和性のアイソフォーム選択的ＴＧＦβ１阻害剤、およびその使用 |
| EA202091888A1 (ru) | 2018-08-08 | 2020-10-23 | Драгонфлай Терапьютикс, Инк. | Вариабельные домены антител, нацеленные на рецептор nkg2d |
| CN115103903A (zh) * | 2019-09-19 | 2022-09-23 | 西北大学 | 用于人诱导型多能干细胞的具成本效益的培养基和操作方案 |
| KR102270700B1 (ko) * | 2019-11-01 | 2021-06-30 | 한국과학기술연구원 | 폐 섬유증의 예방 또는 치료를 위한 올리고뉴클레오티드 중합체와 생체 적합성 양이온성 펩타이드로 이루어지는 폐 특이적 약물 전달체 및 이의 이용 |
| US12157771B2 (en) | 2020-05-06 | 2024-12-03 | Dragonfly Therapeutics, Inc. | Proteins binding NKG2D, CD16 and CLEC12A |
| US20220152025A1 (en) * | 2020-11-17 | 2022-05-19 | United Therapeutics Corporation | Inhaled imatinib for pulmonary hypertension |
| CN112961240B (zh) * | 2021-04-06 | 2022-07-05 | 明济生物制药（北京）有限公司 | 一种靶向TGF-β1的单克隆抗体及其与间充质干细胞外泌体的联合应用 |
| CN112940119B (zh) * | 2021-04-26 | 2022-05-20 | 北京芳渟阳生生物科技有限公司 | 一种单克隆抗体及其与间充质干细胞外泌体的联合应用 |
| WO2023147868A1 (en) * | 2022-02-04 | 2023-08-10 | Justus-Liebig-Universität Giessen | Inhaled imatinib for treatment of pulmonary hypertension |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20020141995A1 (en) * | 1997-06-10 | 2002-10-03 | Irvin Charles G. | Method for treatment of inflammatory disease |
| BRPI0411552A (pt) * | 2003-06-16 | 2006-08-01 | Celltech R & D Inc | anticorpos especìficos a esclerostina e métodos para aumentar a mineralização óssea |
| MXPA06011199A (es) * | 2004-03-31 | 2007-04-16 | Genentech Inc | Anticuerpos anti-tgf-beta humanizados. |
| EP1850873B1 (en) * | 2005-02-08 | 2018-11-28 | Genzyme Corporation | Antibodies to tgfbeta |
| BRPI0620240A2 (pt) | 2005-12-23 | 2011-11-08 | Lilly Co Eli | anticorpo monoclonal, uso do mesmo e composição farmaceutica |
| EP2083863B1 (en) * | 2006-10-03 | 2015-03-18 | Genzyme Corporation | Antibodies to tgf-beta for use in the treatment of infants at risk of developing bronchopulmonary dysplasia |
| BR112013030958B1 (pt) | 2011-06-03 | 2022-02-08 | Xoma Technology Ltd | Anticorpo que se liga ao fator de transformação de crescimento beta, composição farmacêutica, usos dos mesmos, molécula de ácido nucleico, vetor de expressão, e método para produção de um anticorpo |
| EP3415633B1 (en) | 2013-03-11 | 2020-10-28 | Genzyme Corporation | Engineered anti-tgf-beta antibodies and antigen-binding fragments |
| US20170202918A1 (en) | 2014-08-01 | 2017-07-20 | The Brigham And Women's Hospital, Inc. | Methods and compositions relating to treatment of pulmonary arterial hypertension |
| MA44236A (fr) | 2016-02-17 | 2018-12-26 | Novartis Ag | Anticorps anti-tgfbêta 2 |
| EA201991729A1 (ru) | 2017-01-20 | 2019-12-30 | Санофи | Антитела к tgf-бета и их применение |
-
2016
- 2016-06-08 GB GBGB1610044.8A patent/GB201610044D0/en not_active Ceased
-
2017
- 2017-06-07 KR KR1020197000199A patent/KR20190015497A/ko not_active Ceased
- 2017-06-07 EA EA201892774A patent/EA201892774A1/ru unknown
- 2017-06-07 AU AU2017276685A patent/AU2017276685A1/en not_active Abandoned
- 2017-06-07 CN CN201780035444.0A patent/CN109311970A/zh active Pending
- 2017-06-07 SG SG11201810311WA patent/SG11201810311WA/en unknown
- 2017-06-07 JP JP2018564217A patent/JP2019520818A/ja active Pending
- 2017-06-07 US US16/307,444 patent/US10766956B2/en active Active
- 2017-06-07 MX MX2018014376A patent/MX2018014376A/es unknown
- 2017-06-07 AR ARP170101556A patent/AR108779A1/es unknown
- 2017-06-07 CA CA3024011A patent/CA3024011A1/en not_active Abandoned
- 2017-06-07 WO PCT/EP2017/063796 patent/WO2017211873A1/en unknown
- 2017-06-07 RU RU2018146158A patent/RU2746926C2/ru active
- 2017-06-07 BR BR112018074869-2A patent/BR112018074869A2/pt not_active Application Discontinuation
- 2017-06-07 EP EP17729444.4A patent/EP3468992A1/en active Pending
- 2017-06-08 UY UY0001037279A patent/UY37279A/es not_active Application Discontinuation
- 2017-06-08 TW TW106119141A patent/TW201802115A/zh unknown
-
2018
- 2018-11-22 CO CONC2018/0012513A patent/CO2018012513A2/es unknown
- 2018-12-02 IL IL263425A patent/IL263425A/en unknown
- 2018-12-06 CL CL2018003510A patent/CL2018003510A1/es unknown
-
2020
- 2020-07-09 US US16/925,281 patent/US11518803B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| KR20190015497A (ko) | 2019-02-13 |
| US20190330321A1 (en) | 2019-10-31 |
| RU2746926C2 (ru) | 2021-04-22 |
| AU2017276685A1 (en) | 2018-11-29 |
| CA3024011A1 (en) | 2017-12-14 |
| US11518803B2 (en) | 2022-12-06 |
| US20200407436A1 (en) | 2020-12-31 |
| CL2018003510A1 (es) | 2019-02-01 |
| CN109311970A (zh) | 2019-02-05 |
| WO2017211873A1 (en) | 2017-12-14 |
| MX2018014376A (es) | 2019-03-14 |
| GB201610044D0 (en) | 2016-07-20 |
| US10766956B2 (en) | 2020-09-08 |
| UY37279A (es) | 2018-01-31 |
| AR108779A1 (es) | 2018-09-26 |
| IL263425A (en) | 2018-12-31 |
| JP2019520818A (ja) | 2019-07-25 |
| EP3468992A1 (en) | 2019-04-17 |
| CO2018012513A2 (es) | 2019-02-08 |
| RU2018146158A (ru) | 2020-07-09 |
| SG11201810311WA (en) | 2018-12-28 |
| BR112018074869A2 (pt) | 2019-03-26 |
| RU2018146158A3 (ru) | 2020-07-09 |
| TW201802115A (zh) | 2018-01-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EA201892774A1 (ru) | Антитела | |
| EA201690503A1 (ru) | Антитела | |
| CY1121934T1 (el) | Αντισωματα anti-fcrn | |
| PH12018502400A1 (en) | Anti-tim-3 antibodies and methods of use thereof | |
| NZ774326A (en) | Therapeutic antibodies and their uses | |
| EA202090739A1 (ru) | Белки, связывающие антиген созревания в-клеток | |
| PH12019500571A1 (en) | Anti-pd-1 antibodies | |
| EA201892616A1 (ru) | Антитела к pd1 и lag3 для лечения злокачественного новообразования | |
| CY1122214T1 (el) | Αντισωματα ειδικα για ton fcrn | |
| EA201890796A1 (ru) | Новое антитело к мезотелину и содержащая его композиция | |
| EA201491494A1 (ru) | Нацеливание на гликаны хондроитинсульфаты | |
| BR112014028785A2 (pt) | proteínas de ligação a antígeno de st2 | |
| EA201792466A1 (ru) | АНТИТЕЛА ПРОТИВ FcRn | |
| EA201400964A1 (ru) | Cx3cr1-связывающие полипептиды | |
| EA201591791A1 (ru) | Антитела pac1 человека | |
| WO2016063026A3 (en) | Selective nav protein binders | |
| CY1121795T1 (el) | Αντισωματα κατα toy cd52 | |
| MX356502B (es) | Fragmentos de anticuerpos radiomarcados para usarse en la prevencion y/o tratamiento de cancer. | |
| TW201613971A (en) | Anti-epidermal growth factor receptor (EGFR) antibodies | |
| EA201491724A1 (ru) | Антитела, нейтрализующие rsv, mpv и pvm, и их применения | |
| MX389103B (es) | Anticuerpos contra ticagrelor y métodos de uso. | |
| EA201692495A8 (ru) | Биспецифические антитела к il4-il13 | |
| EA201591898A1 (ru) | Антитела, направленные на m-csf | |
| EA202191658A1 (ru) | Антитела против фактора c2b комплемента человека и способы применения | |
| EA202090449A1 (ru) | Связывающие агенты, связывающие pd-l1 и cd137, и их применение |